Zhong Guo Jing Ji Wang·2025-10-30 03:01Core Viewpoint - Fosun Pharma plans to spin off its subsidiary Fosun Antigen (Chengdu) Biopharmaceutical Co., Ltd. for a listing on the Hong Kong Stock Exchange to enhance corporate governance and sustainable development, aiming to maximize shareholder value [1] Group 1: Company Overview - Fosun Antigen was established in July 2012 and is primarily focused on the research, production, and sales of human vaccines, with a technology platform for both bacterial and viral vaccines [1] - Fosun Pharma holds approximately 70.08% of Fosun Antigen, while 17 other shareholders collectively own about 29.92% [1] Group 2: Financial Performance - In 2024, Fosun Antigen reported a revenue of RMB 97.42 million and a net loss of RMB 123.39 million; for the first half of 2025, revenue was RMB 153.16 million with a net loss of RMB 58.45 million [1] - For the third quarter of 2025, Fosun Pharma's revenue was RMB 9.879 billion, a year-on-year decrease of 5.46%, while net profit increased by 4.52% to RMB 821 million [1] - For the first three quarters of 2025, the company reported revenue of RMB 29.393 billion, a year-on-year decline of 4.91%, but net profit increased by 25.5% to RMB 2.523 billion [2]